The effect of new drug approvals on HIV mortality in the US, 1987-1998

Economics and Human Biology

Volumn 1, Issue 2, 2003, Pages 259-266

  Lichtenberg, Frank R ^a  

^a Howard Hughes Medical Institute   (United States)

Author keywords

Antiretroviral therapy; HIV drug approval; HIV mortality; Innovation; Pharmaceuticals; R D

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; OCTREOTIDE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CAUSE OF DEATH; DRUG APPROVAL; DRUG COST; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; UNITED STATES; HUMAN; STANDARD; STATISTICAL MODEL;

ANTI-HIV AGENTS; DRUG APPROVAL; HIV INFECTIONS; HUMANS; MODELS, STATISTICAL; MORTALITY; UNITED STATES;

EID: 0346620161     PISSN: 1570677X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-677X(02)00031-X     Document Type: Article

References (10)

1. DiMasi, J.A., 1995. Trends in drug development costs, times, and risks. Drug Information Journal 29, 375-384.
2. Joint United Nations Programme on HIV/AIDS, 2000. Report on the global HIV/AIDS epidemic. UNAIDS, Geneva, Switzerland, 〈http://hivinsite.ucsf.edu/ InSite.jsp?page=pr-02-01&doc=2098.478b〉.
3. Karon, J.M., Rosenberg, P.S., McQuillan, G., 1996. Prevalence of HIV infection in the United States, 1984-1992. Journal of the American Medical Association 276, 126-131 (http://www.ama-assn.org/special/hiv/library/readroom/ jama96/oc5a84.htm).
4. Lichtenberg, F.R., 2002. Pharmaceutical knowledge-capital accumulation and longevity, 〈http://www.nber.org/~confer/2002/criws02/lichtenberg. pdf〉. In: Corrado, C., Haltiwanger, J., Sichel, D. (Eds.), Measuring Capital in the New Economy. University of Chicago Press, Chicago.
5. Mocroft, A., et al., 1998. Changing patterns of mortality across Europe in patients infected with HTV-1. Lancet 352 (9142), 1725-1730 (November 28).
6. Murphy, K., Topel, R. (Eds.), 2002. Measuring the Gains from Medical Research. University of Chicago Press, Chicago.
7. National Center for Health Statistics, 2001. Healthy People 2000 Final Review. Public Health Service, Hyattsville, MD, 〈http://www.cdc.gov/nchs/ data/hp2000/hp2k01.pdf〉.
8. Palella, F.J., et al., 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 338 (13), 853-860 (March 26, 〈http://www.ama-assn.org/ special/hiv/library/scan/mar98/mar98f.htm〉).
9. Pharmaceutical Research and Manufacturers Association, 2000. PhRMA Industry Profile 2000, 〈http://www. phrma.org/publications/publications/ profile00/index.phtml>.
10. Romer, P.M., 1990. Endogenous technical change. Journal of Political Economy 98, 71-102.